Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Assets (2016 - 2025)

Historic Current Assets for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $113.8 million.

  • Avalo Therapeutics' Current Assets rose 3215.16% to $113.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.8 million, marking a year-over-year increase of 3215.16%. This contributed to the annual value of $138.9 million for FY2024, which is 155443.72% up from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Current Assets is $113.8 million, which was up 3215.16% from $115.2 million recorded in Q2 2025.
  • Avalo Therapeutics' Current Assets' 5-year high stood at $138.9 million during Q4 2024, with a 5-year trough of $7.5 million in Q2 2023.
  • Moreover, its 5-year median value for Current Assets was $47.4 million (2021), whereas its average is $61.2 million.
  • In the last 5 years, Avalo Therapeutics' Current Assets tumbled by 7474.22% in 2022 and then surged by 155443.72% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Current Assets stood at $61.8 million in 2021, then plummeted by 73.46% to $16.4 million in 2022, then plummeted by 48.86% to $8.4 million in 2023, then surged by 1554.44% to $138.9 million in 2024, then decreased by 18.03% to $113.8 million in 2025.
  • Its Current Assets was $113.8 million in Q3 2025, compared to $115.2 million in Q2 2025 and $126.9 million in Q1 2025.